Results 61 to 70 of about 5,144 (141)

Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure

Dermatology and Therapy, 2019
Introduction Long-term safety data are critical for evaluating therapies for psoriasis. Ixekizumab has demonstrated efficacy and is well tolerated for the treatment of moderate-to-severe plaque psoriasis.
April Armstrong, Carle Paul, Luis Puig, Wolf Henning Boehncke, Michael Freeman, Hideshi Torii, Kim Papp, Christopher E. M. Griffiths, Andrew Blauvelt, Kristian Reich, Melinda Gooderham, Tadashi Terui, Lisa Renda, Noah Agada, Wen Xu, Gaia Gallo, Mark G. Lebwohl   +16 more
doaj   +1 more source

Cost per responder for ixekizumab and other biologic drugs approved for the treatment of moderate-to-severe plaque psoriasis in Italy

Global & Regional Health Technology Assessment, 2019
This analysis was aimed at estimating the cost per responder as measured by number needed to treat of ixekizumab as compared with other biologic drugs approved in Italy for the treatment of moderate-to-severe plaque psoriasis.
Roberto Ravasio, Silvia Antonelli, Alessia Maiorino, Antonio Costanzo, Serena Losi   +4 more
doaj   +1 more source

Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab

Patient Preference and Adherence, 2020
Andrew Blauvelt,1 Nianwen Shi,2 Russel Burge,3,4 William N Malatestinic,3 Chen-Yen Lin,3 Carolyn R Lew,2 Nicole M Zimmerman,2 Orin M Goldblum,3 Baojin Zhu,3 Mwangi J Murage3 1Oregon Medical Research Center, Portland, OR, USA; 2IBM Watson Health ...
Blauvelt A, Shi N, Burge R, Malatestinic WN, Lin CY, Lew CR, Zimmerman NM, Goldblum OM, Zhu B, Murage MJ   +9 more
doaj  

Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis

Clinical, Cosmetic and Investigational Dermatology, 2013
Vicky Ren,1 Harry Dao Jr2 1Baylor College of Medicine , School of Medicine, 2Department of Dermatology, Baylor College of Medicine Houston, TX, USA Background: Psoriasis is a debilitating autoimmune skin disease that affects 2%–3% of the world ...
Ren V, Dao Jr H
doaj  

Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry

Drugs - Real World Outcomes
Background Prior work showed that patients from the CorEvitas Psoriasis Registry who had previously failed a prior biologic and then initiated ixekizumab demonstrated improvements in disease severity and patient-reported outcomes after 6 months. However,
Mark Lebwohl, Bruce Strober, Amy Schrader, Alvin H. Li, Thomas Eckmann, Baojin Zhu, William N. Malatestinic, Julie Birt, Meghan Feely, Andrew Blauvelt   +9 more
doaj   +1 more source

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis

Psoriasis: Targets and Therapy, 2017
Sahil Sekhon, Caleb Jeon, Mio Nakamura, Di Yan, Ladan Afifi, Tina Bhutani, Ethan Levin Department of Dermatology, University of California, San Francisco, San Francisco, CA, USA Abstract: Psoriasis vulgaris is a chronic ...
Sekhon S, Jeon C, Nakamura M, Yan D, Afifi L, Bhutani T, Levin E   +6 more
doaj  

26 | CONCOMITANT THERAPY WITH IXEKIZUMAB PLUS TIRZEPATIDE IN ADULTS WITH PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY DEMONSTRATED SUPERIOR DISEASE CONTROL COMPARED TO IXEKIZUMAB ALONE: RESULTS FROM THE PH3B TOGETHER-PSA TRIAL

Dermatology Reports
Background. Overweight and obesity occurs in 72-82%[1,2] of patients with psoriatic arthritis (PsA) and is associated with worse clinical outcomes and increased comorbidities[3].
Associazione Dermatologi-Venereologi Ospedalieri Italiani e della Sanità Pubblica
doaj   +1 more source

Effects of secukinumab and ixekizumab on major adverse cardiovascular events in patients with psoriasis: a meta-analysis of randomized controlled trials

Frontiers in Medicine
IntroductionThe aims of this study is to analyze the risk of major adverse cardiovascular events (MACEs) in patients with psoriasis treated with secukinumab and ixekizumab.MethodologyWe systematically identified randomized controlled trials (RCTs) that ...
Yonghong Zhang, Zhiya Yang, Jinyan Gong, Dongmei Shi, Dongmei Shi   +4 more
doaj   +1 more source

Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy

Drug Design, Development and Therapy, 2017
Alessandro Giunta,1,* Alessandra Ventura,1,* Maria Sole Chimenti,2 Luca Bianchi,1 Maria Esposito1 1Department of Dermatology, 2Department of Rheumatology, University of Rome Tor Vergata, Rome, Italy *These authors contributed equally to this manuscript
Giunta A, Ventura A, Chimenti MS, Bianchi L, Esposito M   +4 more
doaj  

Ixekizumab as a successful treatment in pediatric generalized pustular psoriasis

Italian Journal of Pediatrics
Background Generalized Pustular Psoriasis (GPP) is an autoinflammatory, multisystemic disease, characterized by widespread eruption of neutrophilic pustules on erythematous base, accompanied by systemic symptoms such as fever, leukocytosis, arthralgia ...
Maria Esposito, Paolo Antonetti, Emanuele Vagnozzi, Andrea De Berardinis, Roberta Bertelli, Francesco Brancati, Maria Concetta Fargnoli   +6 more
doaj   +1 more source